The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181

Marijn van der Neut Kolfschoten; Richard J. Dirven; Hans L. Vos; Rogier M. Bertina

doi:10.1055/s-0037-1613370

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2003; 89(03): 429-437
DOI: 10.1055/s-0037-1613370

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181

Marijn van der Neut Kolfschoten

,

Richard J. Dirven

¹Hemostasis and Thrombosis Research Center, Department of Hematology, LUMC, Leiden, The Netherlands

,

Hans L. Vos

¹Hemostasis and Thrombosis Research Center, Department of Hematology, LUMC, Leiden, The Netherlands

,

Rogier M. Bertina

¹Hemostasis and Thrombosis Research Center, Department of Hematology, LUMC, Leiden, The Netherlands

› Author Affiliations

Abstract

Summary

The R2 haplotype of the FV gene spans from exon 8 through 25 and comprises several strongly linked polymorphisms in the FV gene, including some missense mutations. Carriership of the R2-FV allele has been associated with reduced plasma FV levels, increased FV1/FV2 ratios and mild APC resistance. Some studies have reported that carriership of the R2-FV allele is associated with an increased risk of venous thombosis. At this moment, the individual contribution to the R2-associated phenotypes of the different mutations linked to the R2 haplotype of FV is unclear. The main objective of our study was to obtain insight in the influence of the R2-related Asp2194Gly mutation on FV expression, FV structure and FV function using B-domainless rFV mutants. Replacing Asp at position 2194 by Gly resulted in a more than threefold reduction of rFV expression compared to rFV wild-type. Therefore, we propose that the R2-linked Asp2194Gly mutation is an important determinant of the association of the R2-FV allele with lower FV levels. Furthermore, the light chains from Asp2194Gly containing rFV mutants showed similar molecular weights as the light chains of the non-glycosylated rFVwt or the plasma FV2 isoform, indicating that glycosylation at Asn2181 is not stimulated by the presence of a glycine in position 2194. Finally, the apparent K _d for dissociation of the FXaVa complex (K _1/2Xa) was not higher in rFV mutants with the Asp2194Gly mutation than for rFVwt, suggesting that also the affinity for negatively charged phospho-lipids is not affected by substitution of Asp into Gly at position at 2194.

Keywords

Factor V - HR2 - recombinant - glycosylation - expression

Full Text

References

References
1 Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268: 21130-6.
2 Hoekema L, Rosing J, Tans G. An assay to quantify the two plasma isoforms of factor V. Thromb Haemost 2000; 84: 1066-71.
3 Suzuki K, Dahlback B, Stenflo J. Thrombincatalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556-64.
4 Kim SW, Ortel TL, Quinn-Allen MA, Yoo L, Worfolk L, Zhai X, Lentz BR, Kane WH. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry 1999; 38: 11448-54.
5 Nicolaes GA, Villoutreix BO, Dahlback B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry 1999; 38: 13584-91.
6 Ortel TL, Yoo L, Quinn-Allen M, Kane WH. Partial glycosylation at asparagine-2181 of the C-type domain of human factor V is the structural basis of the light chain doublet. Blood 1994; 84: 387a
7 Hoekema L, Nicolaes GAF, Hemker HC, Tans G, Rosing J. Human factor Va₁ and factor Va₂: Properties in the procoagulant and anticoagulant pathways. Biochemistry 1997; 36: 3331-5.
8 Castoldi E, Rosing J, Girelli D, Hoekema L, Lunghi B, Mingozzi F, Ferraresi P, Friso S, Corrocher R, Tans G, Bernardi F. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83: 362-5.
9 Hoekema L, Castoldi E, Tans G, Girelli D, Gemmati D, Bernardi F, Rosing J. Functional properties of factor V and factor Va encoded by the R2-gene. Thromb Haemost 2001; 85: 75-81.
10 Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
11 Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
12 Alhenc-Gelas M, Nicaud V, Gandrille S, van Dreden P, Amiral J, Aubry ML, Fiessinger JN, Emmerich J, Aiach M. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81: 193-7.
13 de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83: 577-82.
14 Kostka H, Siegert G, Schwarz T, Gehrisch S, Kuhlisch E, Schellong S, Jaross W. Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients. Thromb Res 2000; 99: 539-47.
15 Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000; 83: 204-8.
16 Akar N, Akar E, Yilmaz E. Factor V (His 1299 Arg) in Turkish patients with venous thromboembolism. Am J Hematol 2000; 63: 102-3.
17 Pecheniuk NM, Morris CP, Walsh TP, Marsh NA. The factor V HR2 haplotype: prevalence and association of the A4070G and A6755G polymorphisms. Blood Coagul Fibrinolysis 2001; 12: 201-6.
18 Castaman G, Ruggeri M, Tosetto A, Rodeghiero F. Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene. Thromb Haemost 2000; 84: 357-8.
19 Cam-Duchez V, Gandrille S, Tregouet D, Alhenc-Gelas M, Emmerich J, Fiessinger JN, Borg JY, Aiach M. Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation. Br J Haematol 1999; 106: 889-97.
20 Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Finazzi G, Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thrombo-embolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94: 3062-6.
21 Margaglione M, Bossone A, Coalizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E, Di MG. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 2002; 87: 32-6.
22 Kaufman RJ. Vectors used for expression in mammalian cells. Methods Enzymol 1990; 185: 487-511.
23 van der Neut Kolfschoten M, Dirven RJ, Tans G, Rosing J, Vos HL, Bertina RM. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model. Blood Coagul Fibrinolysis 2002; 13: 207-15.
24 Guasch JF, Cannegieter S, Reitsma PH, Van’t Veer-Korthof ET, Bertina RM. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 1998; 101: 32-9.
25 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacterio-phage T4. Nature 1970; 227: 680-5.
26 Lindhout T, Govers-Riemslag JW, van de Waart P, Hemker HC, Rosing J. Factor Va-factor Xa interaction. Effects of phospholipid vesicles of varying composition. Biochemistry 1982; 21: 5494-502.
27 Castaman G, Lunghi B, Missiaglia E, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V leiden) and His1299Arg substitutions in factor V. Br J Haematol 1997; 99: 257-61.
28 Castoldi E. Molecular bases of APC-resistance and Factor V deficiency in thrombophilia. Doctoral thesis. Presso CS; Ferrara: 2001
29 Yamazaki T, Nicolaes GA, Sorensen KW, Dahlback B. Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype. Blood 2002; 100: 2515-21.
30 Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA, Kim SW, Ortel TL, Bourenkov GP, Bartunik HD, Stubbs MT, Kane WH, Fuentes-Prior P. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402: 434-9.
31 Kim SW, Quinn-Allen MA, Camp JT, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry 2000; 39: 1951-8.
32 Kalafatis M, Simioni P, Bernardi F. Phenotype and genotype expression in pseudohomozygous R2 factor V. Blood 2001; 98: 1988-9.
33 Shen L, He X, Dahlbäck B. Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa-factor IXa complex – species specific interactions of components of the protein C anticoagulant system. Thromb Haemost 1997; 78: 1030-6.
34 Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. Thromb Haemost 1995; 73: 730-1.
35 Thorelli E, Kaufman RJ, Dahlback B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140-5.